We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Endothelial Function in a Sample Group of Patients From the ICARE Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00314379
Recruitment Status : Completed
First Posted : April 13, 2006
Last Update Posted : January 22, 2009
Information provided by:

Study Description
Brief Summary:
The ICARE study, clinicaltrials.gov ID number: NCT00220831 and protocol number KL-2004, is recruiting diabetic patients with haptoglobin phenotype 2-2, which are randomised to either Vitamin E 400IU per day or placebo. Patients will be followed for 4 years for the major cardiovascular complications of diabetes, acute myocardial infarction (MI), stroke and cardiovascular mortality (see ICARE protocol). The EFI study, Endothelial Function in ICARE will recruit a sample group of 50 patients from the ICARE cohort. These patients will complete all requirements by ICARE protocol and in addition will be tested for endothelial function by a non-invasive method of flow mediated dilatation (FMD).

Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Drug: Vitamin E 400IU/day Phase 2 Phase 3

Detailed Description:

Fifty patients will be randomly sampled from the ICARE untreated cohort (registry) of diabetic patients with Hp2-2 phenotype which were not randomised to treatment under ICARE study. Patients will be randomised to either vitamin E 400 IU/d or Placebo upon sampling for EFI study.

The patients will be tested for endothelial function by a method of Post Ischemic Flow mediated Dilatation.

all patients will undergo a baseline Endothelial Function test and then start taking the study drug for 2 months. at the end of two months of therapy the patients will undergo a second endothelial function test, then therapy will be stopped for 2 weeks and a cross over will be performed for an additional 2 months of therapy which in the end the third and final endothelial function test will be done.

An interim Results analysis is set to be done once the first 20 patients completed the protocol. In case of significant differences between the groups, study principal investigators will decide about study completion.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Vitamin E Treatment and Endothelial Function in Type 2 Diabetic Patients With Hp 2-2 Phenotype From the I CARE Study (EFI)
Study Start Date : April 2006
Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin E
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. Endothelial function by a non-invasive method of FMD

Secondary Outcome Measures :
  1. Predefined in the protocol submitted to the EC approved prior to study beginning and the Inform Consent Form signed by all study participants prior to study related procedures, serum was preserved for the analysis of oxidative and inflammatory markers.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diabetic patients aged 55 and above

Exclusion Criteria:

  • Patient who takes antioxidant treatment will be asked to stop, or cannot be included in the study.
  • Patients who had a cardiovascular disease (CVD) incident (myocardial infarction [MI], stroke, transient ischemic attack [TIA]), unstable angina pectoris, uncontrolled hypertension (HTN), will have to wait a month after stabilization to be included in the study.
  • Allergy to vitamin E.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00314379

Rambam Medical Center
Haifa, Israel
Sponsors and Collaborators
Technion, Israel Institute of Technology
Clalit Health Services
Rambam Health Care Campus
Principal Investigator: Shany Blum, M.D. M.Sc. Technion, Israel Institute of Technology
Principal Investigator: Uzi Milman, M.D. Clalit Health Services
Principal Investigator: Chen Shapira, M.D. Clalit Health Services
Principal Investigator: Giris Jacob, M.D. Ph.D. Rambam Health Care Campus
Principal Investigator: Lior Dayan, M.D. M.Sc. Rambam Health Care Campus
Principal Investigator: Andrew P Levy, M.D. Ph.D. Technion, Israel Institute of Technology
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00314379     History of Changes
Other Study ID Numbers: HP1980
First Posted: April 13, 2006    Key Record Dates
Last Update Posted: January 22, 2009
Last Verified: January 2009

Keywords provided by Technion, Israel Institute of Technology:
Endothelial Function

Additional relevant MeSH terms:
Cardiovascular Diseases
Vitamin E
Growth Substances
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents